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Worldwide survey of thoracic endografts: Practical
clinical application
Jon S. Matsumura, MD, Chicago, IllINTRODUCTION
This survey was conducted between June 2003 and
June 2004 during personal visits with expert physicians at
several centers of excellence in thoracic endovascular aortic
repair (TEVAR) around the world. They and their col-
leagues deserve specific credit for graciously opening their
labs and sharing their clinical experience in the field.
SURVEY ADVANTAGES AND LIMITATIONS
Peer-reviewed scientific publications are the gold stan-
dard of evidence for medical decision-making. However, in
rapidly emerging technologies, early experiences are dom-
inated by prototype devices, single-site series, and initial
learning periods. Data from United States clinical trials are
useful because of the well-defined protocol, regulatory
oversight, and generally more diligent follow-up and core
lab review. On the other hand, practical clinical use often
does not comply with the rigid entry criteria of these
studies, which were initially designed to evaluate TEVAR
for primarily descending thoracic aneurysms. To get a grasp
of the general clinical practice experience with thoracic
endografts, eight physicians were surveyed (Table I). Their
reflections inform the pooled data on 1180 patients, which
is one of the largest series so far in TEVAR. Limitations of
this compilation are the lack of uniformity in surveillance
protocols, definitions, follow-up intervals, and compliance,
as well as overlap with existing publications.
VARIETY OF DISEASES TREATED
Table II summarizes the types of thoracic pathology
that have been treated and the 30-day mortality for patients
in each of these categories. The impression of most of the
eight physicians is that endovascular treatment is equivalent
to or better than conventional treatment in each of these
categories except for thoracoabdominal aneurysm, chronic
dissection, and aortic stenosis. There was no consensus on
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20Athe relative benefits of TEVAR vs standard therapy for these
three disease states. Most of the patients (64.2%) have been
treated for degenerative descending thoracic aortic aneu-
rysms, and a wide variety of endografts have been used in
treatment (Table III).
Most patients (70.3%) have been treated in an operat-
ing room environment and 49.2% in fixed unit fluoroscopy
units. Intravascular ultrasound was used in 12%, and trans-
esophageal echocardiography in 38.1%. Primary access was
in the femoral artery in 84.4% (percutaneous in 1.1%), iliac
in 7.5%, conduit or aortofemoral graft limb in 6.5%, infra-
renal aorta in 1.1%, and other sites in 0.4%. It is interesting
that the busiest center routinely used a right brachial-
femoral wire and relied upon a portable C-arm with infre-
quent use of ultrasound.
The left subclavian artery was covered in 29.8%, the left
common carotid in 8.0%, the innominate in 3.7%, celiac
artery in 3.1%, and superior mesenteric artery in 0.8%. With
more experience, debranching procedures, fenestrations,
scallops, and branches are being performed. The option to
revascularize these major branches is exercised at different
rates: most centers revascularize the carotid, innominate,
and visceral arteries when they are covered. In contrast,
revascularization is performed before or concurrently with
TEVAR in only 36.7% of patients who have coverage of the
left subclavian artery. Many centers have decreased use of
routine subclavian revascularization except when there are
diseased or hypoplastic right vertebral arteries or fistulas/
reconstructions based on left subclavian branches. Most
patients are managed expectantly; when symptoms develop
after left subclavian coverage, which is unusual, delayed
revascularization is performed.
Spinal cord drainage was used sparingly in 1.0% but in
up to 6.8% of patients with extensive descending aortic
coverage or history of abdominal aortic aneurysm. Utiliza-
tion of spinal cord drainage, arterial line pressure monitor-
ing, and aggressive blood pressure support may be on the
increase as TEVAR is applied to more diffuse pathology.
Adenosine (2.1%) and high-dose -blocker (0.1%) were
used rarely to arrest or slow the heart for deployment and
are becoming obsolete with newer device delivery technol-
ogies.
The 30-day morbidity rates reflect stroke in 2.8%, renal
failure in 1.6%, and paraplegia in 2.5%. As the stroke rate is
higher than the paraplegia rate, extensive deairing is prac-
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43% of the paraplegia complications were delayed in onset
and reversible in a significant portion of patients.
Later outcomes are best described by time-dependent
intervals; unequal or unknown lengths of follow-up make
precision impossible in this compilation. Nevertheless, gen-
eral estimates are useful to characterize TEVAR. Endoleak
Table I. Expert physicians and institutions by
TEVAR volume
Physician Location
Volume in
survey
Shin Ishimaru, MD Tokyo Medical
University
384
Michael Dake, MD Stanford University
Medical School
300
Roy Greenberg, MD The Cleveland Clinic 223
Ludger Sunder-Plassman,
MD
University of Ulm 106
Rodney White, MD Harbor-UCLA Medical
Center
78
Geoffrey White, MD University of Sydney 50
Takao Ohki, MD Montefiore Medical
Center
20
Michael Laurence-Brown,
MD
Perth University 19
TEVAR, Endovascular repair of thoracic pathology; UCLA, University of
California, Los Angeles.
Table II. Various aortic pathologies treated by
endovascular thoracic repair and periprocedural mortality
Primary aortic pathology
Percent of
total cases
30-day
mortality (%)
Degenerative aneurysm
Descending thoracic aneurysm 64.2 4.1
Thoracoabdominal aneurysm 1.6 5.0
Post-traumatic
Acute traumatic disruption 10.0 5.5*
Pseudoaneurysm 3.3 2.7
Dissection
Acute dissection 7.8 9.9
Intramural hematoma with ulcer 2.2 7.2
Giant penetrating ulcer 1.0 0
Chronic dissection 8.4 3.3
Miscellaneous
Aortic fistula 0.9 2.6
Embolizing lesion 0.3 0
Stenosis/coarctation 0.1 0
*Most deaths related to associated traumatic injuries.was noted in 10.5% of patients, sac expansion in 4.0%,proximal neck dilation or dissection in 2.7%, distal neck
dilation in 2.1%, intercomponent migration in 1.7%, prox-
imal migration in 1.3%, distal migration in 0.4%, asymp-
tomatic device failure such as fracture in 6.3%, symptomatic
device failure in 0.1%, and aneurysm rupture in 0.9%.
Although these rates are low, some of the complications are
catastrophic, such as proximal aortic dissections and perfo-
rations.
CONCLUSION
The treatment of thoracic aortic disease is rapidly evolv-
ing followingUnited States Food andDrug Administration
approval of one device for treatment of descending thoracic
aneurysms. Alternatives to the traditional open surgical
approach to dissection, transection, and other less common
pathology are being developed and applied in centers of
excellence. Mortality rates for open surgical repair of the
thoracic aorta have decreased with experience, but early
reports of thoracic aortic endografts support TEVAR as a
less-invasive option with lower morbidity and periproce-
dural mortality rates.
Several engineering advancements are being pursued to
address shortcomings in earlier devices for thoracic endo-
vascular repair. These include endografts that conform to
the individual aortic anatomy, more flexible and accurate
delivery systems, more robust construction to accommo-
date higher thoracic aortic forces, and mechanisms to treat
pathology close to or involving the aortic arch and visceral
side branches. As these technologies mature, it is quite
possible that TEVAR will become the preferred initial
therapy for many thoracic aortic diseases.
Table III. Distribution of endovascular grafts
in this compilation
Endograft Frequency
Custom made 53.6
TAG* 19.0
Zenith† 11.5
Talent‡ 10.8
AneuRx‡ 2.9
Infrarenal cuffs 1.9
Other 0.3
*W.L. Gore & Assoc., Flagstaff, Ariz.
†Cook, Bloomington, Ind.
‡Medtronic Inc, Minneapolis, Minn.Submitted Oct 19, 2005; accepted Oct 23, 2005.
